Mark Cuban (Sam Hodde/AP Images)
July 14, 2023 02:17 PM EDT
Pharma
Marketing

Mark Cuban's Cost Plus Drug Com­pa­ny adds new SGLT2 in­hibitor Bren­zavvy for type 2 di­a­betes

Nicole DeFeudis

Editor

Mark Cuban’s Cost Plus Drug Com­pa­ny is bring­ing an­oth­er brand-name type 2 di­a­betes treat­ment un­der its wing.

Ther­a­cos­Bio’s re­cent­ly ap­proved SGLT2 in­hibitor Bren­zavvy is now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times